Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis.
Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis.
复制标题
DOI：
10.12688/f1000research.4709.1
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Fiehn O
中科院分区：
文献类型：
--
作者：
Armstrong AW;Wu J;Johnson MA;Grapov D;Azizi B;Dhillon J;Fiehn O
重要性：虽然“组学”研究增进了我们对炎症性皮肤病的理解，但代谢组学在皮肤病学领域基本上是一个未经探索的领域。 目的：我们试图通过确定患有或不患有银屑病关节炎的银屑病患者与健康对照之间代谢组学特征的差异来阐明银屑病的发病机制。 设计：我们采用全局代谢组学方法来比较银屑病患者、银屑病和银屑病关节炎患者以及健康对照的循环代谢物。 背景：研究参与者是从普通社区和美国加州大学戴维斯分校银屑病诊所招募的。 参与者：我们使用 30 名年龄和性别匹配的患者的血清样本检查了代谢组学特征，这些患者被分为三组：10 名银屑病患者、10 名银屑病和银屑病关节炎患者以及 10 名对照参与者。 主要结果和措施：通过气相色谱飞行时间质谱计算平均峰强度来测量代谢水平。 结果：代谢组学概况的多变量分析揭示了研究人群中血清代谢物的改变。与对照患者相比，银屑病患者的α酮戊二酸水平较高（Pso：288±88；对照：209±69；p=0.03），天冬酰胺水平较低（Pso：5460±980；对照：7260±2100；p=0.02），谷氨酰胺水平较低（Pso： 86000±20000；控制： 111000±27000； p=0.02）。与对照患者相比，银屑病和银屑病关节炎患者的葡萄糖醛酸水平升高（Pso + PsA：638 ± 250；对照：347 ± 61；p = 0.001）。与单纯银屑病患者相比，同时患有银屑病和银屑病关节炎的患者的α酮戊二酸水平降低（Pso + PsA：186 ± 80；Pso：288 ± 88；p=0.02），而二十四烷酸水平升高（Pso + PsA：442 ± 280；Pso：214 ± 64；Pso：214 ± 64）。 p=0.02）。 结论和相关性：代谢物差异有助于阐明银屑病和银屑病关节炎的发病机制，并可能为治疗开发提供见解。
Importance: While “omics” studies have advanced our understanding of inflammatory skin diseases, metabolomics is mostly an unexplored field in dermatology. Objective: We sought to elucidate the pathogenesis of psoriatic diseases by determining the differences in metabolomic profiles among psoriasis patients with or without psoriatic arthritis and healthy controls. Design: We employed a global metabolomics approach to compare circulating metabolites from patients with psoriasis, psoriasis and psoriatic arthritis, and healthy controls. Setting: Study participants were recruited from the general community and from the Psoriasis Clinic at the University of California Davis in United States. Participants: We examined metabolomic profiles using blood serum samples from 30 patients age and gender matched into three groups: 10 patients with psoriasis, 10 patients with psoriasis and psoriatic arthritis and 10 control participants. Main outcome(s) and measures(s): Metabolite levels were measured calculating the mean peak intensities from gas chromatography time-of-flight mass spectrometry. Results: Multivariate analyses of metabolomics profiles revealed altered serum metabolites among the study population. Compared to control patients, psoriasis patients had a higher level of alpha ketoglutaric acid (Pso: 288 ± 88; Control: 209 ± 69; p=0.03), a lower level of asparagine (Pso: 5460 ± 980; Control: 7260 ± 2100; p=0.02), and a lower level of glutamine (Pso: 86000 ± 20000; Control: 111000 ± 27000; p=0.02). Compared to control patients, patients with psoriasis and psoriatic arthritis had increased levels of glucuronic acid (Pso + PsA: 638 ± 250; Control: 347 ± 61; p=0.001). Compared to patients with psoriasis alone, patients with both psoriasis and psoriatic arthritis had a decreased level of alpha ketoglutaric acid (Pso + PsA: 186 ± 80; Pso: 288 ± 88; p=0.02) and an increased level of lignoceric acid (Pso + PsA: 442 ± 280; Pso: 214 ± 64; p=0.02). Conclusions and relevance: The metabolite differences help elucidate the pathogenesis of psoriasis and psoriatic arthritis and they may provide insights for therapeutic development.